Tagged with

clinical trials You are the CEO of GCP CMIC ClinPlus in addition to R&G PharmaStudies, and before that you headed a number of companies as well. Could you introduce yourself and all the many moving parts you lead to our readers? To begin with, I was a physician for 10 years before…

Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…

Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…

Eisai Eisai has a history of more than 40 years in Indonesia. In fact, the country was one of the first places for the Group to expand into outside of Japan. Indonesia has already increasingly entered the international spotlight, but how does this apply to Eisai? It seems the Group has…

Can you trace the evolution of the Colombian economy over the last few years? The Colombian economy is experiencing a time of significant growth with production and investment projects as key driving forces of development. Since 2010, Colombia has shown an average Gross Domestic Product (GDP) growth of 5.1%, positioning the…

Nordic Last year, Boston Scientific took important steps to stabilise and strengthen its core businesses. Could you develop on the development trajectory of Boston Scientific in the Nordic region so far? I have only been with the company for a year now, but what happened is that Boston Scientific have acquired…

Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…

Gary Goodyear, Minister for Science, shares with us how the Canadian Government has taken a different approach to funding innovation and the benefits it has reaped in the pharma industry as a whole in the country. You became Minister of State for Science and Technology in 2008, a position that…

Goodyear Minister for Science shares with us how the Canadian Government has taken a different approach to funding innovationand the benefits it has reaped in the pharma industry as a whole in the country. You became Minister of State for Science and Technology in 2008, a position that had previously not…

Rx&D You have been President of Rx&D since 2004, and have witnessed the market’s development over the years. What have been the most important issues since you started and what are you most proud of? Our industry is developing partnerships with governments, universities, patient groups, biotechs to bring about the best…

Nordics Mary Di Marzio has been General Manager of Nordics for Shire Inc for nearly 2 years now. Today she shares with Pharmaboardroom the progress of Shire’s relatively new branch in Scandinavia. She continues to give insights into the balancing act between pricing versus reimbursement and how they are raising awareness…

abbott  Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is there still work to be done? Abbott is a global diversified healthcare company which comprises several businesses in Indonesia, including…